Second Dose of BNT162b2 COVID-19 Vaccine Demonstrates Significant Immunogenicity Increase in Population With Solid Tumors
Patients with solid tumors experienced significant immunogenicity within 2 weeks of receiving a second dose of the BNT162b2 COVID-19 vaccine.